Clinical Effects of Dietary Supplementation of Lutein with High Bio-Accessibility on Macular Pigment Optical Density and Contrast Sensitivity: A Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Trial

Improvements in macular pigment optical density (MPOD) and contrast sensitivity after administration of 12 mg lutein alone and the timing at which efficacy is observed remain unknown. Therefore, lutein (12 mg), a crystalline formulation, was used in this study, considering its bioaccessibility. This study aimed to determine the effects of lutein administration for 16 weeks on MPOD, contrast sensitivity, and glare sensitivity, and changes in serum lutein levels were determined. The study subjects comprised 59 healthy male and female adults aged 20–69 years. The study diet included a placebo (placebo group) or a diet supplemented with 12 mg of lutein (lutein group). Each study diet was continuously administered for 16 weeks. At weeks 8 and 16, MPOD, contrast sensitivity, glare sensitivity, and serum lutein levels were evaluated. Compared with the placebo group, the lutein group showed significantly improved MPOD, contrast sensitivity, and glare sensitivity at week 16 and significantly increased serum lutein levels at weeks 8 and 16. Continuous administration of lutein for 16 weeks, considering its bioaccessibility, increased MPOD; it made the outlines of visible objects clearer and was effective in inhibiting decreases in visual function caused by glare from light.

Download Full-text

Measuring the Temporal Contrast Sensitivity Function and Macular Pigment Optical Density in Older Adults with and Without Cognitive Impairment

Journal of Vision ◽

10.1167/11.15.35 ◽

2011 ◽

Vol 11 (15) ◽

pp. 35-35

Author(s):

M. Dengler ◽

A. Thorne ◽

A. Puente ◽

A. Watts ◽

B. Hammond ◽

...

Keyword(s):

Older Adults ◽

Cognitive Impairment ◽

Contrast Sensitivity ◽

Optical Density ◽

Macular Pigment ◽

Sensitivity Function ◽

Contrast Sensitivity Function ◽

Macular Pigment Optical Density ◽

Temporal Contrast

Download Full-text

Bioavailability of lutein/zeaxanthin isomers and macular pigment optical density response to macular carotenoid supplementation: A randomized double blind placebo controlled study

New Frontiers in Ophthalmology ◽

10.15761/nfo.1000132 ◽

2016 ◽

Vol 2 (4) ◽

Cited By ~ 1

Author(s):

Vijaya Juturu ◽

James P Bowman ◽

Nicole T. Stringham ◽

James M. Stringham

Keyword(s):

Optical Density ◽

Macular Pigment ◽

Controlled Study ◽

Macular Pigment Optical Density ◽

Double Blind ◽

Double Blind Placebo ◽

Density Response ◽

Carotenoid Supplementation

Download Full-text

Efficacy of Commercially Available Nutritional Supplements: Analysis of Serum Uptake, Macular Pigment Optical Density and Visual Functional Response

Nutrients ◽

10.3390/nu12051321 ◽

2020 ◽

Vol 12 (5) ◽

pp. 1321

Author(s):

Richard A. Bone ◽

Pinakin Gunvant Davey ◽

Betzabe O. Roman ◽

David W. Evans

Keyword(s):

Contrast Sensitivity ◽

Optical Density ◽

Visual Function ◽

Nutritional Supplements ◽

Serum Levels ◽

Macular Pigment ◽

Macular Pigment Optical Density ◽

Significant Elevation ◽

Carotenoid Concentration ◽

Serum Carotenoids

Purpose: To compare the change in serum carotenoids, macular pigment optical density (MPOD) and visual function with the intake of two commercially available nutritional supplements. Methods: Participants were given a 24-week supply of a lipid-based micronized liquid medical food, Lumega-Z™ (LM), containing 28 mg of the macular carotenoids lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ), or given PreserVision™ AREDS 2 Formula (gel-caps; PV) containing 12 mg of the macular carotenoids L and Z, but no reported MZ. Serum levels of L, Z and MZ were obtained at baseline and after 12 weeks. Macular pigment optical densities (MPOD) and visual function were assessed at baseline and after 24 weeks. Results: Average blood serum concentrations of L, Z and MZ in the two groups at baseline were similar. The increases in L, Z and MZ were 0.434, 0.063 and 0.086 µmol/L vs. 0.100, 0.043 and 0.001 µmol/L, respectively, in the LM vs. PV group. From baseline to week 24, average MPOD in the LM-group increased by 0.064 from 0.418 to 0.482, whereas in the PV-group, it was essentially unchanged (0.461 to 0.459;). Although log-contrast sensitivity was improved in all groups under three conditions (photopic, mesopic and mesopic with glare), the change in log-contrast sensitivity was not statistically significant. Conclusion: Despite only a 2.3-fold higher carotenoid concentration than PV, LM supplementation provides approximately 3–4-fold higher absorption, which leads to a significant elevation of MPOD levels.

Download Full-text

The role of the macular pigment optical density measurement in the diagnosis of eye diseases

Clinical ophthalmology ◽

10.21689/2311-7729-2016-16-4-197-200 ◽

2016 ◽

Vol 16 (4) ◽

pp. 197-200

Author(s):

E.N. Eskina ◽

◽

E.A. Egorov ◽

A.V. Belogurova ◽

А.А. Gvetadze ◽

...

Keyword(s):

Optical Density ◽

Density Measurement ◽

Macular Pigment ◽

Eye Diseases ◽

Macular Pigment Optical Density ◽

Optical Density Measurement

Download Full-text

Macular Pigment Optical Density and Photoreceptor Outer Segment Length as Predisease Biomarkers for Age-Related Macular Degeneration

Journal of Clinical Medicine ◽

10.3390/jcm9051347 ◽

2020 ◽

Vol 9 (5) ◽

pp. 1347 ◽

Cited By ~ 1

Author(s):

Norihiro Nagai ◽

Sakiko Minami ◽

Misa Suzuki ◽

Hajime Shinoda ◽

Toshihide Kurihara ◽

...

Keyword(s):

Macular Degeneration ◽

Optical Density ◽

Outer Segment ◽

Macular Pigment ◽

Age Related Macular Degeneration ◽

Segment Length ◽

Macular Pigment Optical Density ◽

Photoreceptor Outer Segment ◽

Age Related ◽

Fellow Eyes

To explore predisease biomarkers, which may help screen for the risk of age-related macular degeneration (AMD) at very early stages, macular pigment optical density (MPOD) and photoreceptor outer segment (PROS) length were analyzed. Thirty late AMD fellow eyes, which are at high risk and represent the predisease condition of AMD, were evaluated and compared with 30 age-matched control eyes without retinal diseases; there was no early AMD involvement in the AMD fellow eyes. MPOD was measured using MPS2® (M.E. Technica Co. Ltd., Tokyo, Japan), and PROS length was measured based on optical coherence tomography images. MPOD levels and PROS length in the AMD fellow eyes were significantly lower and shorter, respectively, than in control eyes. MPOD and PROS length were positively correlated in control eyes (R = 0.386; p = 0.035) but not in AMD fellow eyes. Twenty (67%) AMD fellow eyes met the criteria of MPOD < 0.65 and/or PROS length < 35 μm, while only five (17%) control eyes did. After adjusting for age and sex, AMD fellow eyes more frequently satisfied the definition (p < 0.001; 95% confidence interval, 3.50–60.4; odds ratio, 14.6). The combination of MPOD and PROS length may be a useful biomarker for screening predisease AMD patients, although further studies are required in this regard.

Download Full-text

Macular pigment optical density in central serous chorioretinopathy

Therapeutic Advances in Ophthalmology ◽

10.1177/2515841421997195 ◽

2021 ◽

Vol 13 ◽

pp. 251584142199719

Author(s):

Burcu Polat Gultekin ◽

Esra Sahli

Keyword(s):

Confidence Interval ◽

Optical Density ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Retinal Thickness ◽

Macular Pigment ◽

Central Retinal Thickness ◽

Macular Pigment Optical Density ◽

Chronic Central Serous Chorioretinopathy ◽

Acute Central Serous Chorioretinopathy

Purpose: The aim of our study was to evaluate the macular pigment optical density in patients with acute and chronic central serous chorioretinopathy and to describe the association between central retinal thickness and choroidal thickness with the macular pigment optical density. Materials and Methods: Eyes with acute central serous chorioretinopathy and chronic central serous chorioretinopathy (patients, who were diagnosed as having disease activity for 6 months) were included in this study. Macular pigment was measured using the heterochromatic flicker technique of the MPS II device for both eyes in patients with acute and chronic central serous chorioretinopathy and in control subjects. Results: Twenty-seven eyes with acute central serous chorioretinopathy, 23 eyes with chronic central serous chorioretinopathy, and 25 control eyes were enrolled. The mean macular pigment optical density in chronic central serous chorioretinopathy (0.480 ± 0.16 density unit (95% confidence interval: 0.390–0.570) was found to be significantly lower than in the control eyes (0.571 ± 0.128 density unit) (95% confidence interval: 0.480–0.670) ( p = 0.007). In correlation analysis, no significant association was detected between the central retinal thickness, choroidal thickness, and macular pigment optical density values in central serous chorioretinopathy group ( p = 0.31, p = 0.71). Conclusion: Macular pigment optical density levels were significantly lower in chronic central serous chorioretinopathy patients than in controls, possibly due to degeneration of the neurosensorial retina, as a result of the long-term persistence of subretinal fluid. There was not a significant correlation between choroidal thickness and macular pigment optical density levels in central serous chorioretinopathy group.

Download Full-text